NCT07089303

Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

Ultra-high Field Multimodal and Multinuclear Neuroimaging Cohort Study of Alzheimer's Disease

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 750 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Accepted

Summary

This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)). At baseline and at annual follow-ups, participants will undergo 3 Tesla (3 T) and 7 Tesla (7 T) multimodal magnetic resonance imaging (MRI) scans, blood biomarker testing, genotyping, and cognitive assessments to identify early imaging biomarkers and construct models of disease progression.

Detailed description

This prospective, single-center cohort will enroll 750 participants (normal controls, MCI, and AD) for at least four years of follow-up. Using ultra-high field 7T multimodal and multinuclear (hydrogen-1 \[¹H\], sodium-23 \[²³Na\]) MRI, combined with plasma biomarkers and genetic data, the study aims to identify early neuroimaging biomarkers and clarify the clinical significance of sodium metabolic abnormalities in AD. Structural, functional, and sodium imaging data will be integrated with neuropsychological and blood-based markers, using artificial intelligence for early diagnosis and risk prediction. The study will address technical gaps in early detection and provide the first standardized 7T AD neuroimaging database for the Chinese population.

Conditions

• Alzheimer Disease
• Mild Cognitive Impairment Due to Alzheimer's Disease

Timeline

• Start date: 2025-07-01
• Primary completion: 2029-07-01
• Completion: 2029-08-01
• First posted: 2025-07-28
• Last updated: 2025-08-14

Locations

1 site across 1 country: China